A number of HSP90 inhibitors have demonstrated anti-myeloma activity in pre-clinical studies and at least three compounds have been evaluated in Phase I trials for relapsed/refractory myeloma [2-5]. The gene discussed is HSP90AA1; the disease is plasma cell myeloma.